Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Blood Adv bloodadvances.2024014975.

https://doi.org/10.1182/bloodadvances.2024014975

Published: 2025

Includes: Supplemental data

Journal Articles

Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

Blood Adv bloodadvances.2024015282.

https://doi.org/10.1182/bloodadvances.2024015282

Published: 2025

Includes: Supplemental data

Journal Articles

Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Blood Adv bloodadvances.2024015600.

https://doi.org/10.1182/bloodadvances.2024015600

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

Blood Adv bloodadvances.2025016117.

https://doi.org/10.1182/bloodadvances.2025016117

Published: 2025

Includes: Supplemental data

Journal Articles

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, John M. Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian Topp, Pallavi M Pillai, Alex F. Herrera

Blood Adv bloodadvances.2024014654.

https://doi.org/10.1182/bloodadvances.2024014654

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

Blood Adv (2025) 9 (12): 2927–2934.

https://doi.org/10.1182/bloodadvances.2024014790

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Martina Cantelli, Gabriele Gugliotta, Marianna Gentilini, Matteo Carella, Vittorio Stefoni, Cinzia Pellegrini, Nicole Fabbri, Giulia Gabrielli, Camilla Mazzoni, Pierluca Maglio, Gianmarco Bagnato, Pier Luigi Zinzani

Blood Adv (2025) 9 (9): 2044–2047.

https://doi.org/10.1182/bloodadvances.2024015581

Published: 2025

Journal Articles

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Matthew J. Maurer, Susan K. Parsons, Jenica N. Upshaw, Angie Mae Rodday, Raphael Mwangi, Sára Rossetti, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Pier Luigi Zinzani, Andrew M. Evens

Blood Adv (2025) 9 (6): 1366–1369.

https://doi.org/10.1182/bloodadvances.2024014689

Published: 2025

Journal Articles

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M. McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T. MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yuri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, Henry Miles Prince, Ramzi Hamouche, Tinatin Murdashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O’Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood Adv (2025) 9 (3): 583–602.

https://doi.org/10.1182/bloodadvances.2024014674

Published: 2025

Includes: Supplemental data

Journal Articles

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Blood Adv (2024) 8 (18): 4866–4876.

https://doi.org/10.1182/bloodadvances.2024013236

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Zinzani, Ann S. LaCasce, Peter D. Cole, Craig H. Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Müller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M. Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood Adv (2024) 8 (11): 2740–2752.

https://doi.org/10.1182/bloodadvances.2023012145

Published: 2024

Includes: Supplemental data

Journal Articles

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Blood Adv (2024) 8 (10): 2400–2404.

https://doi.org/10.1182/bloodadvances.2023011030

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson

Blood Adv (2024) 8 (4): 867–877.

https://doi.org/10.1182/bloodadvances.2023010648

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani

Blood Adv (2023) 8 (1): 93–98.

https://doi.org/10.1182/bloodadvances.2023010636

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Blood Adv (2023) 7 (22): 6801–6811.

https://doi.org/10.1182/bloodadvances.2023010668

Published: 2023

Includes: Supplemental data

Journal Articles

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, Gabriele Gugliotta, Matteo Carella, Paolo Elia Coppola, Gianmarco Bagnato, Pier Luigi Zinzani

Blood Adv (2023) 7 (21): 6762–6766.

https://doi.org/10.1182/bloodadvances.2023010742

Published: 2023

Includes: Supplemental data

Journal Articles

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Blood Adv (2023) 7 (20): 6266–6274.

https://doi.org/10.1182/bloodadvances.2023010334

Published: 2023

Includes: Supplemental data

Journal Articles

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz

Blood Adv (2023) 7 (18): 5272–5280.

https://doi.org/10.1182/bloodadvances.2023010254

Published: 2023

Includes: Supplemental data

Journal Articles

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Blood Adv (2023) 7 (16): 4435–4447.

https://doi.org/10.1182/bloodadvances.2022009575

Published: 2023

Includes: Supplemental data

Journal Articles

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Adv (2022) 6 (19): 5550–5555.

https://doi.org/10.1182/bloodadvances.2020003971

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only